<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079131</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01446</org_study_id>
    <secondary_id>03-105</secondary_id>
    <secondary_id>CDR0000354418</secondary_id>
    <secondary_id>NCI-5907</secondary_id>
    <secondary_id>MSKCC-03105</secondary_id>
    <secondary_id>N01CM62207</secondary_id>
    <secondary_id>N01CM62206</secondary_id>
    <nct_id>NCT00079131</nct_id>
  </id_info>
  <brief_title>Oblimersen in Treating Patients With Merkel Cell Carcinoma</brief_title>
  <official_title>A Phase II Study of G3139 (Genasense â„¢) in Patients With Merkel Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well oblimersen works in treating patients with Merkel&#xD;
      cell cancer. Biological therapies, such as oblimersen, may interfere with the growth of tumor&#xD;
      cells and slow the growth of Merkel cell carcinoma (skin cancer).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the overall response rate in patients with Merkel cell carcinoma treated with&#xD;
      oblimersen.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the time to progression in patients treated with this drug. II. Determine the&#xD;
      response duration in patients treated with this drug. III. Determine the safety and&#xD;
      tolerability of this drug in these patients. IV. Determine the pharmacodynamic effects of&#xD;
      this drug on bcl-2 expression and apoptosis in tumor biopsy specimens from these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive oblimersen IV continuously on days 1-14. Courses repeat every 21 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Interval between the start of treatment and until the criteria for progression are met, assessed up to 3 years</time_frame>
    <description>Progression-free survival probabilities will be computed using Kaplan-Meier methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events, assessed using revised NCI CTC version 3.0</measure>
    <time_frame>Within 30 days of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Recurrent Neuroendocrine Carcinoma of the Skin</condition>
  <condition>Stage I Neuroendocrine Carcinoma of the Skin</condition>
  <condition>Stage II Neuroendocrine Carcinoma of the Skin</condition>
  <condition>Stage III Neuroendocrine Carcinoma of the Skin</condition>
  <condition>Stage IV Neuroendocrine Carcinoma of the Skin</condition>
  <arm_group>
    <arm_group_label>Treatment (oblimersen sodium)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oblimersen IV continuously on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>oblimersen sodium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (oblimersen sodium)</arm_group_label>
    <other_name>augmerosen</other_name>
    <other_name>G3139</other_name>
    <other_name>G3139 bcl-2 antisense oligodeoxynucleotide</other_name>
    <other_name>Genasense</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (oblimersen sodium)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (oblimersen sodium)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed Merkel cell carcinoma&#xD;
&#xD;
               -  Metastatic OR regionally recurrent disease&#xD;
&#xD;
               -  Localized disease not amenable to curative therapy (surgery or radiotherapy) also&#xD;
                  allowed&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
               -  Previously resected or irradiated brain metastases allowed if stable for at least&#xD;
                  the past 3 months and no evidence of neurological compromise exists&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  WBC &gt;= 3,000/mm^3&#xD;
&#xD;
          -  AST/ALT =&lt; 2.5 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  INR =&lt; 1.5&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance &gt;= 60 mL/min&#xD;
&#xD;
          -  No atrial fibrillation unless stable for at least the past 6 months&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Adequate venous access&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  No active or ongoing infection&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No prior grade 3 or 4 anaphylactic reaction to phosphorothioate oligonucleotide&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  More than 3 weeks since prior chemotherapy and recovered&#xD;
&#xD;
          -  More than 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy to 25% or more of bone marrow&#xD;
&#xD;
          -  More than 3 weeks since prior investigational therapy and recovered&#xD;
&#xD;
          -  No prior oblimersen&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent anticoagulation except 1 mg of warfarin for mediport patency&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ki Chung</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2004</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oblimersen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

